https://orcid.org/0000-0001-6295-211X
References
- Ribatti D. The chick embryo chorioallantoic membrane (CAM). a multifaceted experimental model. Mech Dev. 2016;141:70–77.
- Deryugina EI, Quigley JP. Chapter 2. Chick embryo chorioallantoic membrane models to quantify angiogenesis induced by inflammatory and tumor cells or purified effector molecules. Methods Enzymol. 2008;444:21–41.
- Ribatti D. Chicken chorioallantoic membrane angiogenesis model. Methods Mol Biol. 2012;843:47–57.
- Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with imageJ. Biophot Int. 2004;11:36–42.
- Parisi GF, Licari A, Papale M, et al. Antihistamines: ABC for the pediatricians. Pediatr Allergy Immunol. 2020;31 (24):34–36.
- Bergmann KC, Ring J, editors. History of allergy. Chem immunol allergy. Basel, Switzerland: Karger; 2014. p.302–310.
- Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–257.
- Shamizadeh S, Brockow K, Ring J. Rupatadine: efficacy and safety of a non-sedating antihistamine with PAF-antagonist effects. Allergo J Int. 2014;23(3):87–95.
- Drolet AM, Thivierge M, Turcotte S, et al. Platelet-activating factor induces Th17 cell differentiation. Mediators Inflamm. 2011;2011:913802.
- Wu LQ, Ouyang XY, Liu Y, et al. Inhibitory effects of SY0916, a platelet-activating factor receptor antagonist, on the angiogenesis of human umbilical vascular endothelial cells. J Asian Nat Prod Res. 2011;13(11):984–992.
- Ma X, Ottino P, Bazan HE, et al. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest Ophthalmol Vis Sci. 2004;45(9):2915–2921.
- Bussolati B, Biancone L, Cassoni P, et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol. 2000;157(5):1713–1725.
- Bussolino F, Arese M, Montrucchio G, et al. Platelet activating factor produced in vitro by Kaposi’s sarcoma cells induces and sustains in vivo angiogenesis. J Clin Invest. 1995;96(2):940–952.
- Lordan R, Tsoupras A, Zabetakis I. The potential role of dietary Platelet-Activating factor inhibitors in cancer prevention and treatment. Adv Nutr. 2019;10(1):148–164.
- Sun L, He Z, Ke J, et al. PAF receptor antagonist gingkgolide B inhibits tumourigenesis and angiogenesis in colitis-associated cancer. Int J Clin Exp Pathol. 2015;8(1):432–440.
- Zhang H, Yang Y, Takeda A, et al. A novel Platelet-Activating factor receptor antagonist inhibits choroidal neovascularization and subretinal fibrosis. PLoS One. 2013;8(6):e68173.
- Tsoupras AB, Iatrou C, Frangia C, et al. The implication of platelet activating factor in cancer growth and metastasis: potent beneficial role of PAF-inhibitors and antioxidants. Infect Disord Drug Targets. 2009;9(4):390–399.
- Montrucchio G, Sapino A, Bussolati B, et al. Potential angiogenic role of platelet-activating factor in human breast cancer. Am J Pathol. 1998;153(5):1589–1596.
- Ramis I, Giral M, Ferrando R, et al. Inhibition of PAF and LTB4-induced human neutrophil chemotaxis by rupatadine using a new fluorescent chemotaxis assay. Allergy. 2000;55(63):94–95.
- Barrón S, Roman J, Michelena P, et al. Rupatadine inhibits cytokine production and NF-κB activity by histamine H1 receptor-dependent mechanism. Rev Rinol. 2006;6:18.
- Mullol J, Bousquet J, Bachert C, et al. Rupatadine in allergic rhinitis and chronic urticaria. Allergy. 2008;63(s87):5–28.